The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.

As sales of the Japanese drugmaker’s non-hormonal treatment for menopausal symptoms Veozah finally take off, the German major has filed its potential competitor, elinzanetant, with the US Food and Drug Administration.

The UK biotech unveils Phase II data showing an ability to reduce severity of mild-to-moderate AA, with full hair restoration in some patients. If approved, STS-01 will compete with Olumiant and Litfulo.

The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.